ANI Pharmaceuticals (NASDAQ:ANIP) Issues Earnings Results

ANI Pharmaceuticals (NASDAQ:ANIP) announced its quarterly earnings results on Friday. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77, FiscalAI reports. ANI Pharmaceuticals had a return on equity of 27.97% and a net margin of 8.87%.The company had revenue of $237.46 million during the quarter, compared to analyst estimates of $207.63 million. During the same quarter in the previous year, the firm posted $1.70 EPS. The firm’s quarterly revenue was up 20.5% on a year-over-year basis. ANI Pharmaceuticals updated its FY 2026 guidance to 9.190-9.690 EPS.

Here are the key takeaways from ANI Pharmaceuticals’ conference call:

• ANI raised its 2026 guidance, now targeting $1.08B–$1.14B in revenue, $285M–$300M adjusted EBITDA and $9.19–$9.69 adjusted EPS, driven by rare disease strength.
• Cortrophin Gel revenue grew 42% YoY to $75.1M in Q1, April saw the highest new patient starts since launch, and a 64‑rep commercial expansion into primary care and podiatry is being deployed to accelerate H2/2026 and 2027 growth.
• ANI recognized a $15M upfront fee from an out‑license to Harmony Biosciences, expects an additional $10M in near‑term development milestones (Q2–Q3) and low‑single‑digit royalties on pitolisant (WAKIX), adding immediate cash and future royalty upside.
• Generics continue to fund growth with Q1 generics revenue of $105.4M (up 7%), six new launches YTD and a steady 10–15 launch cadence, while management authorized a new $100M share repurchase program as part of disciplined capital allocation.
• Q1 results were impacted by insurance reverification delays and weather‑related office closures that temporarily depressed early‑quarter Cortrophin volumes and contributed to a lower non‑GAAP gross margin (60.8%), and ILUVIEN still faces ongoing Medicare access challenges.

ANI Pharmaceuticals Trading Down 2.4%

Shares of NASDAQ ANIP traded down $2.05 during mid-day trading on Friday, hitting $81.86. 1,218,429 shares of the company traded hands, compared to its average volume of 402,621. ANI Pharmaceuticals has a 1 year low of $56.71 and a 1 year high of $99.50. The stock has a market capitalization of $1.83 billion, a price-to-earnings ratio of 24.36 and a beta of 0.46. The company has a quick ratio of 2.19, a current ratio of 2.71 and a debt-to-equity ratio of 1.11. The business has a 50 day moving average of $76.82 and a two-hundred day moving average of $81.01.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Zacks Research upgraded ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 15th. Wall Street Zen lowered ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 14th. Finally, Guggenheim upped their price objective on ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a report on Friday, January 16th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $107.33.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, VP Meredith Cook sold 500 shares of the company’s stock in a transaction on Monday, April 13th. The stock was sold at an average price of $77.95, for a total transaction of $38,975.00. Following the completion of the sale, the vice president directly owned 78,890 shares of the company’s stock, valued at $6,149,475.50. This represents a 0.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 2,060 shares of the company’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $76.50, for a total value of $157,590.00. Following the sale, the senior vice president directly owned 84,782 shares of the company’s stock, valued at approximately $6,485,823. This represents a 2.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 27,860 shares of company stock valued at $2,111,581 over the last 90 days. 8.10% of the stock is owned by insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several hedge funds have recently modified their holdings of ANIP. Arrowstreet Capital Limited Partnership purchased a new stake in shares of ANI Pharmaceuticals during the third quarter valued at $32,992,000. Balyasny Asset Management L.P. lifted its holdings in shares of ANI Pharmaceuticals by 2,785.7% during the third quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock valued at $26,211,000 after purchasing an additional 276,233 shares during the last quarter. Rubric Capital Management LP lifted its holdings in shares of ANI Pharmaceuticals by 354.7% during the second quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock valued at $16,813,000 after purchasing an additional 200,998 shares during the last quarter. UBS Group AG lifted its holdings in shares of ANI Pharmaceuticals by 45.8% during the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after purchasing an additional 185,172 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC lifted its holdings in shares of ANI Pharmaceuticals by 780.8% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 192,006 shares of the specialty pharmaceutical company’s stock valued at $15,157,000 after purchasing an additional 170,206 shares during the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

Key ANI Pharmaceuticals News

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Q1 results materially beat expectations: EPS $2.05 vs. consensus $1.28 and revenue $237.5M vs. $207.6M (revenue +20.5% YoY). Strong top‑ and bottom‑line beats support a re-rating. Read More.
• Positive Sentiment: Management raised FY‑2026 EPS guidance to $9.190–$9.690, above the street consensus (~$8.79), signaling stronger full‑year profitability and underpinning upside to estimates. Read More.
• Neutral Sentiment: Management commentary and details are available in the Q1 earnings call transcript and slide deck for investors who want cadence on product mix, margins, and cadence of revenue. Read More.
• Neutral Sentiment: Analyst and media pieces highlight the beat and guidance raise and walk through key metrics vs. Street and year‑ago results — useful for modeling revisions. Read More.
• Negative Sentiment: Valuation and balance‑sheet points to watch: trailing PE (~25) and debt/equity (~1.11) could limit near‑term upside and increase sensitivity to any guidance misses or margin pressure. Investors should model whether higher FY EPS justifies current multiples. Read More.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.